Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Nature. 2021 Oct 11;600(7889):523–529. doi: 10.1038/s41586-021-04085-y

Extended Data Table 1 |. SARS-CoV-2 Vaccinated Cohort.

Exact counts for each demographic category are displayed in each cell with accompanying standard deviations for each measurement. Percentages of total, where applicable, are provided in parenthesis. In cases where specific demographic information was missing, the total number of patients with complete information used for calculations is provided within the cell.

Vaccine Sex SeroStatus
Age (years) Moderna Pfizer Female Male Negative Positive
Total Cohort % #DIV/0! 80.56 19.44 80.56 19.44 50.0 50.0
Non- Previous exposed % 44.28 (1.833 ± 4.242) 61.11 38.88 77.7 83.33
Previous exposed % 46.11 (1.833 ± 4.242) 100.0 0.0 22.22 16.66
 
Volunteers ID Age range Sex SeroStatus Vaccine Age Range
1 B Female Negative Pfizer A 26–35
2 B Female Negative Pfizer B 36–45
3 B Female Negative Moderna C 46–55
4 C Female Negative Moderna D 56–65
5 C Female Negative Pfizer E 66–75
6 B Female Negative Pfizer
7 E Female Negative Moderna
8 B Female Negative Moderna
9 C Male Negative Moderna
10 A Female Negative Pfizer
11 B Female Negative Moderna
12 B Male Negative Moderna
13 D Male Negative Moderna
14 A Female Negative Moderna
15 D Female Negative Pfizer
16 B Female Negative Moderna
17 A Female Negative Moderna
18 C Male Negative Pfizer
20 D Female Positive Moderna
21 A Female Positive Moderna
22 D Female Positive Moderna
24 E Female Positive Moderna
25 C Female Positive Moderna
26 B Female Positive Moderna
27 C Male Positive Moderna
28 D Female Positive Moderna
30 A Male Positive Moderna
31 A Female Positive Moderna
32 C Female Positive Moderna
33 A Female Positive Moderna
34 A Female Positive Moderna
35 C Female Positive Moderna
36 D Female pOsitive Moderna
37 D Female Positive Moderna
38 D Female Positive Moderna
39 A Male Positive Moderna